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Abstract
Background: Epithelial ovarian cancer (EOC) typically spreads intra-abdominally, but preoperative evaluation with
FDG PET/CT often reveals metabolically active supradiaphragmatic lymph nodes (sdLNs). Their clinical significance
and behavior during treatment has not been established.
Methods: EOC patients with PET positive sdLNs at diagnosis were prospectively followed with PET/CT after primary
chemotherapy and at the first recurrence. In each patient, 2 most active LNs in 5 different supradiaphramatic
regions were evaluated and the size and changes in FDG uptake (SUVmax) were recorded. The patients´ overall
response to primary treatment was defined with RECIST criteria. The behavior of sdLNs during chemotherapy were
compared in treatment responders and non-responders. Recurrence patterns were monitored.
Results: Forty-one patients with 127 PET/CT scans were systematically evaluated. In pretreatment scan, 76% (31/41)
of patients had FDG-avid sdLNs in multiple anatomical sites. Only a minority (22/136) of the sdLNs were enlarged in
size, but their histopathologic confirmation by biopsy was not possible. Only 6/41 patients had FDG-avid sdLNs in a
single surgically approachable site. The sdLNs became inactive during primary chemotherapy more often in the
RECIST responders compared to the non-responders (HR 1.46 (95%CI: 1.09–1.96), p = 0.002). The size and SUVmax
values did not predict treatment outcome. In 50% of the responders the same sdLNs reactivated when recurrence
occurred. Persistent post-treatment metabolic activity did not predict earlier disease relapse (p = 0.59).
Conclusion: The behavior of metabolically active sdLNs during chemotherapy supports their metastatic nature. Due
to their distribution to multiple regions, the benefit of removal of reachable sdLNS seems unlikely.
Trial registration: NCT, NCT01276574. Registered 1 September 2010.
Keywords: FDG-PET/CT, Ovarian cancer, FDG-avid supradiaphragmatic lymph nodes
Introduction
The vast majority of EOC is diagnosed at an advanced
stage [1] and optimal removal of intraabdominal tumor
bulk forms a major prognostic factor for survival [2, 3].
The need to extend cytoreductive surgery outside the
abdominal cavity has recently been a focus of interest.
Increasing evidence indicates that abnormal [18F]-fluor-
o-2-deoxy-D-glucose (FDG) accumulation in sdLNs is a
common finding in advanced EOC [4–6]. International
Federation of Gynecology and Obstetrics (FIGO) staging
system requires histopathological verification of extra-ab-
dominal metastases [7]. Pretreatment positron emission
computed tomography (PET/CT) may reveal small supra-
diaphragmatic lymph node metastases (sdLNM) unreach-
able for sampling. In addition, the common presence of
FDG-avid sdLNs suggests that many FIGO stage IIIC pa-
tients actually have extra-abdominal disease. Radiological
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suspicion of sdLNM can cause confusion while staging the
OC and choosing the treatment modality.
Although there are limited data on the clinical signifi-
cance of the radiologically detected extra-abdominal dis-
ease spread, it has been suggested that FDG-avid sdLNs
may be a predictive parameter in advanced EOC for the
failure of optimal cytoreduction [8], the probability of
neoadjuvant chemotherapy (NACT) as the primary
intervention [9], the lower rate of complete initial treat-
ment response [8, 9] and inferior survival [10]. The
standard surgical management of EOC is aimed at the
removal of the intra-abdominal lesions.
We have earlier presented results from a prospectively
recruited cohort of advanced EOC patients, where 20/30
patients were found to have PET positive sdLNs at the
time of diagnosis [4]. In the present study, we aim to
evaluate the FDG-avid sdLNs’ pretreatment characteristics,
and their response to first line chemotherapy and patterns
of recurrence by means of a thorough radiologic follow-up
in patients without intrathroracic debulking. In addition,
we aim to assess the predictive value of sdLNs size and
SUVmax to treatment outcome, and the impact of sdLNs
metabolic response to progression free survival (PFS).
Methods
Patients
The current patient cohort was collected as part of pro-
spective clinical MUPET trial (ClinicalTrials.gov Identi-
fier: NCT01276574) and treated at Turku University
Hospital’s Department of Obstetrics and Gynecology be-
tween Oct 2009 and Feb 2014.
Fifty-five patients with stage IIIB-IVB serous EOC
were included, 41 (74%) of them had FDG-avid sdLNs in
the pretreatment FDG-PET/CT scan and comprised the
final study cohort. The patients with other previous ma-
lignancies and diabetes were excluded. The patients’
characteristics are presented in Table 1. FDG-PET/CT
scans were performed at the following stages: a) the pre-
operative assessment, b) after NACT prior to interval
debulking surgery (IDS), c) after the first line standard
platinum-taxane based chemotherapy, and d) at the time
of the first relapse of the disease (Fig. 1). The number of
FDG-PET/CT scans was 2–4 per patient.
SdLNs were not surgically removed in any of the pa-
tients. The selection of the treatment schedule was
based on clinical examination, preoperative FDG-PET/
CT, and diagnostic laparoscopy or laparotomy. Ultra-
sound guided biopsies from FDG-PET/CT positive
sdLNs (N = 5) were taken when feasible. Patients who
underwent surgery (N = 36) received 3–6 cycles of adju-
vant chemotherapy after operation and patients with
progressive disease after NACT (N = 5) were not oper-
ated and were changed over second line chemotherapy.
PET/CT scanning procedure and data analysis
A whole-body contrast-enhanced FDG-PET/CT was
performed with either a 64-row Discovery STE or a VCT
(General Electric Medical Systems, Milwaukee, WI,
USA). Imaging studies were performed prior to the
treatment, after NACT, 4 weeks after the last cycle of
the adjuvant chemotherapy and at the first relapse of the
disease. All patients fasted for a minimum of 6 h and
their serum glucose level was controlled before the
intravenous injection of the 4 Mbq/kg 18F-FDG isotope.
The low-dose PET/CT (kV 120, Smart mA range 10–80)
from skull base to mid-thigh was performed 50–60 min
after the tracer injection. It was followed by a
whole-body diagnostic high dose contrast-enhanced CT
Table 1 Patients’ characteristics
Variables Patients (n) %
Total 41 100
Age, median (years,range) 63 (30–80)
FIGO stage
IIIB 2 4.9
IIIC 18 43.9
IVA 6 14.6
IVB 15 36.6
Histology
High grade serous 37 90.2
Low grade serous 4 9.8
Treatment strategy
Primary debulking surgery 12 29.3
Neoadjuvant chemotherapy 29 70.7
Interval debulking surgery 24 58.5
PDS outcome
No residual tumor 3 25.0
Residual tumor size < 1 cm 4 33.3
Residual tumor size > 1 cm 5 41.7
IDS outcome
No residual tumor 6 25.0
Residual tumor size < 1 cm 17 70.8
Residual tumor size > 1 cm 1 4.2
Primary treatment outcome
Complete response 20 48.8
Partial response 9 22.0
Stable disease 0 0
Progressive disease 12 29.2
Recurrence rate after completion of first line therapy (N = 29)
All patients 26 89.7
Complete response 14 46.2
Partial response 12 53.8
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scan (kV 120, Smart mA range100–440), after the auto-
mated intravenous injection of a contrast agent. PET
images were reconstructed with a 128 × 128 matrix size
in a fully 3D mode using an ML-OSEM reconstruction
algorithm. Imaging analysis was performed using an
ADW4.5 workstation.
Two dedicated nuclear medicine experts analyzed the
integrated FDG-PET/high dose contrast-enhanced CT im-
ages. PET imaging analysis was performed using an ADW
4.5 workstation. The evaluation was systematic and in-
cluded all anatomical sites. PET positive (FDG-avid) find-
ings were collected into a detailed worksheet in order to
compare the change in the standardized uptake value
(SUVmax) and size in the PET/CT scans of the same LNs,
taken at different time points. Typical physiologically ac-
tive FDG-avid sites were excluded. The SUVmax values
were corrected for body weight and injected dose.
For LN based analysis, supradiaphragmatic area was
divided into five anatomical regions: cardiophrenic,
parasternal, mediastinal (including hilar area), axillary
and subclavian [4]. The two most metabolically active
LNs from each anatomical site were evaluated. The
SUVmax values were calculated, but no specific cutoff
value for SUVmax defining the LNs as metastatic was
applied. In patients receiving NACT FDG-avid retroperi-
toneal lymph node metastases in paraaortic and parailiacal
sites were evaluated.
The patients’ response to first line treatment was evalu-
ated according to the criteria of Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 [11] and
CA-125 criteria of The Gynecological Cancer Intergroup
(GCIC) [12]. The treatment response evaluation was based
on contrast enhanced CT and the serum marker CA-125,
not PET/CT. Metabolic response in an individual sdLN
was considered complete when the SUVmax value did not
differ from that of the surrounding background after initial
therapy, and partial when the reduction of FDG uptake was
a minimum of 30% [13]. All of the patients had regular
Fig. 1 Study outline and overview of the treatment modalities
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check-ups with clinical status and serum CA-125 controls
after completion of first line chemotherapy. Imaging studies
were performed when clinical symptoms suggesting relapse
occurred. Recurrence of the disease was defined as con-
stantly elevated levels of CA-125 tumor marker or anatom-
ical progression in CT scan.
In order to compare the behavior of the FDG-avid
sdLNs in patients with different clinical outcomes, the
patients who according to RECIST 1.1 and GCIC criteria
had obtained at least a partial response after the completion
of adjuvant chemotherapy were considered first line ther-
apy responders (responders), while those with a stable or
progressive disease where categorized as non-responders.
Statistical analyses
All statistical analyses were performed using JMP Pro 12
software from SAS. Continuous variables between the two
groups were compared using a Mann-Whitney U-test. Fish-
er’s exact test was used in the analysis of contingency tables
to summarize the relationship between categorical vari-
ables. Kaplan-Meier survival curves for PFS of study pa-
tients were compared with a log rank test for all variables.
PFS was defined as the time interval from the diagnosis
until the disease progression or death. P-values < 0.05 were
considered statistically significant.
Results
In total, 127 PET/CT scans were analyzed. Forty-one
patients (75%) of 55 had FDG-avid sdLNs (N = 136) in
preoperative FDG-PET/CT. The responders group con-
sisted of 29 patients with 97 FDG-avid sdLNs prior to
therapy and the non-responders group included 12 pa-
tients with 39 FDG-avid sdLNs. One to nine sdLNs per
patient (mean 3.3) were analyzed.
FDG-avid sdLNs in preoperative PET/CT
Of the 136 FDG-avid sdLNs, 16% (22/136) sdLNs were
enlarged (short axis ≥ 10mm). The size, SUVmax values
and distribution of FDG-avid sdLNs in preoperative PET/
CT is presented in Fig. 2. There was no statistically signifi-
cant difference in the average size and SUVmax values of
FDG-avid sdLNs in preoperative imaging between the re-
sponders and non-responders (p = 0.84 and 0.29).
Of the 41 patients, 31 (76%) had metabolically active
sdLNs in multiple anatomical sites (Table 2, Fig. 2). 76%
(31/41) had preoperatively FDG-avid LNs in the cardio-
phrenic area, that could potentially be resected in sur-
gery. Notably, in 6 patients this was the only FDG-avid
sdLN station.
The behavior of FDG-avid sdLNs in response to the
primary treatment
The behavior of sdLNs during primary therapy reflected
the patients’ overall chemotherapy response.
The metabolic response of 97 preoperatively detected
FDG-avid sdLNs in responders and 39 in non-responders
group were evaluated. After the completion of the first
line chemotherapy, 96% (93/97) of the FDG-avid sdLNs in
responders group responded metabolically to the treat-
ment, 82.5% (80/97) with complete and 13.4% (13/17) par-
tial metabolic response. In the non-responders group,
despite the disease progression elsewhere, 22 (56%) of the
preoperatively FDG-avid 39 sdLNs showed complete
metabolic response, whereas 21% (8/39) showed partial
metabolic response.
The sdLNs in the responders group more frequently
showed a complete metabolic resolution after primary
treatment compared to the non-responders group, haz-
ard ratio 1.46 (95%CI: 1.09–1.96) (p = 0.002).
Of the sdLNs that were still metabolically active in the
response evaluation PET/CT, there had been a mean de-
cline in the SUV max values of 42% in the responders
group compared to only 20% in the non-responders
group (p = 0.02).
The same tendency, although not statistically signifi-
cant, was detected when analyzed at the level of the in-
dividual patients: the 35% (10/29) of patients in the
responders group and 71% (7/12) in the non-responders
group had FDG avid sdLNs in the response evaluation
scan (p = 0.18) (Table 2).
Similar to retroperitoneal LNM, the metabolic re-
sponse to chemotherapy in FDG-avid sdLNs was already
detectable after NACT (Table 3).
The FDG-avid sdLNs profile at the first disease relapse
The FDG-avid sdLNs which responded to first line
chemotherapy often reactivated during disease recur-
rence. Disease recurrence in the thorax alone was rare.
Figure 3 presents the behavior of preoperatively detected
FDG-avid sdLNs of our study patient in FDG-PET/CT
during primary treatment until the first recurrence.
The responders (n = 29) had regular follow-up visits
after completion of primary therapy. Within the median
follow-up time of 35.8 months (95% Cl: 31.7–41.0), 90%
(26/29) responders experienced disease recurrence and
69% (20/29) died. The median PFS of responders was 14
months (95% Cl: 1.1–18.4). There was no difference in
median PFS of patients with complete and partial meta-
bolic response in FDG-avid sdLNs (13,6 vs 14.9 months),
respectively (p = 0.59).
The overall distribution of the disease when relapse
occurred is presented in Additional file 1: Table S1. In
50% (11/22) of first line responders the same sdLNs acti-
vated when recurrence was detected.
Biopsies from FDG-avid sdLNs were pre-operatively
taken from five patients and malignant histology was
confirmed in all 5 cases (4 axillary and 1 subclavicular
LNM). Two of the confirmed sdLN metastases were
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enlarged (≥10mm) and 3 normal (< 10 mm) in size. The
mean preoperative SUV max of the confirmed sdLN
metastases was 3.3 and their metabolic response to first
line chemotherapy was complete. The size and preopera-
tive SUVmax values of the confirmed sdLN metastases
did not differ statistically that from the not biopsied
FDG-avid sdLNs.
Discussion
Detection of metabolically active sdLNs have been re-
ported in a number of studies using PET/CT imaging
[5, 6, 9, 10, 14, 15]. These findings often lack histo-
logic confirmation, since anatomical sites such as the
parasternal and mediastinal lymph chain are unreach-
able for biopsy. Radiologic follow-up is an indirect
method to confirm their malignant nature. To the
best of our knowledge, the current study is the first
one designed for prospective and systematic monitor-
ing of the behavior of FDG-avid sdLNs with repeated
PET/CT scans during treatment and relapse.
Our data suggest that the FDG-avid sdLNs do repre-
sent metastatic infiltration and are not artefactual or re-
active changes. In line with previous studies [5, 10, 14],
our follow up including 127 meticulously analyzed PET/
CT scans showed that the vast majority of sdLNs accu-
mulating FDG are normal in size. The metastatic nature
Fig. 2 The size and the SUVmax of FDG-avid supradiaphragmatic lymph nodes (sdLNs) in the preoperative PET/CT of 41 patients with advanced EOC
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of FDG avid sdLNs is suggested by two findings. Firstly,
similar to the patients’ other lesions (including retroperi-
toneal LNM), FDG-avid sdLNs respond to first line
chemotherapy both in a per-lesion and in a per-patient
assessment. The metabolic response was similar in
FDG-avid sdLNs and retroperitoneal LNM already after
NACT prior any debulking surgery was performed.
Secondly, in half of the patients, the same sdLNs reac-
tivated and enlarged during the recurrence. The number
of histopathologically confirmed sdLNM was small
(N = 5). However, FDG-PET/CT finding led to histo-
logical sampling of the hot spot and upstaging the dis-
ease from FIGO stage IIIC to IVB in all of these
patients. The confirmed sdLNM also showed complete
metabolic response to first line chemotherapy and often
reactivated at the time of recurrence. In addition to de-
crease in SUVmax values, sdLNs that were detectable
after first line treatment decrease in size after treatment
Fig. 3 The preoperative whole body PET/CT maximum intensity projection view of the patient with FIGO stage IIIC high grade EOC show, in
addition to the abdominal involvement, an extensive FDG uptake in cardiophrenic, parasternal, mediastinal, subclavicular, neck and axillary lymph
nodes (a). After 3 cycles of NACT, an interval debulking surgery (with no gross residual disease) and 3 cycles of standard adjuvant taxane-platinum
based chemotherapy the FDG uptake has been normalized (b). PET/CT performed 11 months after the end of primary treatment shows metabolic
reactivation of paraaortal and supradiaphragmatic lymph nodes as well as new metabolically active supradiaphragmatic lymph nodes (c).
Transaxial PET/CT fusion images show the preoperatively detected FDG-avid lymph node profile during treatment and relapse in the neck (d,e,f)
as well as in the axillary (white arrow) and mediastinal (yellow arrow) (g,h,i) regions
Table 3 The metabolic response of supradiaphragmatic and retroperitoneal lymphnodes to neoadjuvant chemotherapy
Response to first
line treatment
Supradiaphragmatic
lymphnodes
Retroperitoneal
lymphnodes
p value
Complete response after NACT responders 65% (39/60) 68% (23/34) 0.82
non-responders 30% (11/37) 40% (8/20) 0.55
Mean decrease in SUVmax in sdLNs with
partial metabolic response
responders 42% 67% 0.13
non-responders 20% 27% 0.90
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and thickened when relapse was detected. However, the
change was only a few millimeters and sdLNs were all
along normal in size.
The prognostic significance of the PET positive sdLNs
in pretreatment scan may be limited. Neither the size
nor the SUVmax of sdLNs in the pretreatment scan pre-
dicted the patients’ primary therapy outcome. Compared
to patients with complete metabolic resolution in sdLNs
post treatment, partial metabolic response to the initial
therapy was not associated with earlier disease relapse.
In addition, in the majority of sdLNs in non-responders
group showed some metabolic response, albeit progres-
sion of the disease in the abdominal cavity. This weakens
the prognostic value of sdLNs as their metabolic re-
sponse to the treatment does not seem to reflect the dis-
ease status in the abdomen nor instructs the possible
further treatment.
In agreement with previous reports [10, 16, 17], we found
that among patients with suspected extra-abdominal dis-
ease the recurrence to the thorax alone is rare and the most
common site of the first relapse is the abdomen. The multi-
directional migration of malignant cells and the reseeding
of the primary tumor by metastasis has been demonstrated
in human prostate cancer [18]. Post treatment residual
metastatic infiltration in sdLNs may theoretically also rep-
resent a reservoir of malignant cells in OC. In present
study, some patients had large volume residual disease in
abdominal cavity after surgery and therefore any conclu-
sions on role of sdLNs as cancer reservoir cannot be
concluded.
Resection of enlarged cardiophrenic LNs has been re-
ported to be a safe and feasible procedure for patients
with advanced EOC [19–22]. However, there is contro-
versial data about the survival benefit of extending PDS
outside the abdominal cavity [10, 22, 23] and no consen-
sus over the cutoff for pathologic cardiophrenic LNs.
Values ranging between 5 and 10mm have been suggested
[19, 24, 25]. In our cohort, the majority of FDG-avid
sdLNs were normal in size (when cutoff ≥10mm for en-
larged was used) and they were most commonly localized
in the cardiophrenic and parasternal areas. However, only
a small proportion of patients had all of the metabolically
suspicious sdLNs in surgically approachable area.
The role of routine retroperitoneal lymphadenectomy of
normal size nodes has been questioned in advanced EOC,
since it is reported not to improve patients’ outcome
[26, 27]. It can be anticipated that this is also liable to
be the case with sdLNs. Garbi et al. [21] recently re-
ported no recurrences in the cardiophrenic angle when
debulked during PDS. Since they did not use PET/CT
preoperatively or in the follow up, the status of other
sdLNs was not known. In a recent study of Lee et al
[10], primary debulking of sdLNM did not improve sur-
vival. In our study, only a minority of advanced EOC
patients with intrathoracic disease had FDG-avid sdLNs in
a single surgically approachable anatomical site. That may
raise questions about the benefit of removing only the sus-
picious cardiophrenic LNs. We suggest that the centers
committing cardiophrenic LNs resection should consider
performing FDG-PET/CT covering also thorax area prior
to surgery and during the follow-up in order to clarify the
clinical significance of detected FDG-avid sdLNs and the
survival benefit of cardiophrenic surgery in EOC.
This study has certain limitations including the ab-
sence of histological verification of sdLNMs in the ma-
jority of patients (36/41), restriction in the assessment of
prognostic significance due to the small number and
heterogenous characteristics of patients. The strengths
of our study are the prospectively designed, systematic
and detailed evaluation of the FDG-avid sdLNs behavior
with PET/CT throughout the disease, and the long
follow-up time of the patients.
Conclusions
FDG-avid sdLNs are common in patients with advanced
EOC. FDG-avid sdLNs are often unsuspicious in conven-
tional imaging modalities, and unreachable for histopatho-
logical verification. In addition, they are often distributed
over multiple anatomical sites which precludes complete
surgical removal. Our comprehensive follow-up study sup-
ports the metastatic nature of FDG-avid sdLNs detected
with PET/CT. Unremoved FDG-avid sdLNs responded
metabolically to chemotherapy and often reactivated during
disease recurrence. The prognostic significance of favorable
metabolic treatment response in detected FDG-avid sdLNs
in EOC patients is limited. For survival analyses further
controlled studies with an adequate control group are
needed.
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